Rafael Simó: "We should talk about "obesities" instead of "obesity" because more and more... 06/06/2024 Healthcare Access to innovation Drug discovery Geneis Biomed interviews Dr. Rafael Simón, head of the Endocrinology and Nutrition Department at Vall d'Hebron... Partners - GENESIS Biomed
Use of biotechnology in advanced therapies and new technologies in the spanish market 03/06/2024 Healthcare Access to innovation Advanced therapies Among the most important emerging technologies are the manipulation of the microbiota, CAR-T cell therapies, and gene... Partners - KONEXIO BIOTECH
Oryzon announces journal publication of final Phase IIa ALICE results with iadademstat in ... 03/06/2024 Healthcare Access to innovation Rare diseases Innovative drugs Advanced therapies The Phase IIa study ALICE evaluated the combination of iadademstat plus azacitidine in newly diagnosed, unfit patients... Partners - Oryzon Genomics
Oryzon selected as Associated Partner in the first Important Project of Common European In... 29/05/2024 Healthcare Access to innovation Drug discovery Rare diseases Innovative drugs Personalized medicine Financing Commission has approved up to €1 billion of State aid by six Member States: Belgium, France, Hungary, Italy, Slovakia... Partners - Oryzon Genomics
Collaboration, efficient management of intellectual property and creation of spin-offs, vi... 29/05/2024 Healthcare Access to innovation AseBio has organized, within the framework of the XVII Annual Conference of Biomedical Research Technology Platforms... AseBio
Collaboration, efficient management of intellectual property and creation of spin-offs, vi... 29/05/2024 AseBio has organized, within the framework of the XVII Annual Conference of Biomedical Research Technology Platforms... AseBio
Four AseBio partners will participate in the first IPCEI in the health sector that will mo... 29/05/2024 Healthcare Access to innovation Financing The Major Project of Common European Interest 'Med4Cure' will enable member states to support a total of 14 projects... AseBio
Key Considerations for Cell and Gene Therapy Commercialization in Non-Orphan Indications 29/05/2024 Healthcare Access to innovation Drug discovery There are two important challenges for companies aiming to develop CGTs in mainstream indications. Partners
Miramoon Pharma Receives Orphan Drug Designation for MP-004 28/05/2024 Healthcare Access to innovation Rare diseases Innovative drugs Orphan Drug Designation is a special status granted by the FDA to drugs that are intended to treat rare diseases or... Partners - Miramoon Pharma
Atlas Molecular Pharma successfully completes phase one in humans of its treatment for Con... 28/05/2024 Healthcare Access to innovation Drug discovery Rare diseases Innovative drugs Personalized medicine The final results of ATL-001, the biotech company's lead candidate, have shown that it is able to stabilize UROIIIS and... Partners - Inveready
